FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1857930572> ?p ?o ?g. }

• W1857930572 endingPage "374" @default.
• W1857930572 startingPage "368" @default.
• W1857930572 abstract "Background: In patients with coronary artery disease (CAD), there is an increasing therapeutic need among interventional cardiologists to conduct dual antiplatelet therapy (DAPT) whose duration is shorter than current guideline-recommended 6–12 months after the implantation of drug-eluting stents. However, no clinical grounds sufficient to rationalize the need are available. Objectives: To define the optimal duration of DAPT and to examine the safety and efficacy of the Endeavor zotarolimus-eluting stent (E-ZES) in real-world Japanese patients with CAD. Study design: The present prospective, nonrandomized, multicenter, controlled study is uniquely designed to examine the analysis set to be formulated after integrating two different databases consisting of the following two study arms: the 3-month DAPT arm, in which 1,210 patients were consecutively enrolled at 106 medical institutions; and the 12-month DAPT arm, in which 1,210 patients will be consecutively extracted from the Endeavor Japan post-marketing surveillance at 60 medical institutions. The primary endpoint is “net adverse cardiac and cerebrovascular events—death, myocardial infarction, cerebrovascular accident, and major bleeding)” at 12 months after implantation. The secondary endpoints are as follows: major adverse cardiac events at 1, 3, 6, 9, and 12 months after implantation; target vessel revascularization and target lesion revascularization at 9 and 12 months after implantation; and stent thrombosis, DAPT compliance, and bleeding events at 12 months after implantation. Noninferiority in the E-ZES's profiles between the study arms will be investigated. Conclusions: The present study will provide insight into the optimal duration of DAPT after the E-ZES implantation in individual, real-world patients with CAD. © 2013 Wiley Periodicals, Inc." @default.
• W1857930572 created "2016-06-24" @default.
• W1857930572 creator A5001421629 @default.
• W1857930572 creator A5003621363 @default.
• W1857930572 creator A5005993128 @default.
• W1857930572 creator A5012624832 @default.
• W1857930572 creator A5022678421 @default.
• W1857930572 creator A5023883550 @default.
• W1857930572 creator A5029785850 @default.
• W1857930572 creator A5037592709 @default.
• W1857930572 creator A5052154025 @default.
• W1857930572 creator A5062108209 @default.
• W1857930572 creator A5071117344 @default.
• W1857930572 creator A5077511836 @default.
• W1857930572 creator A5078418468 @default.
• W1857930572 date "2013-12-31" @default.
• W1857930572 modified "2023-09-23" @default.
• W1857930572 title "Optimal duration of dual antiplatelet therapy following treatment with the endeavor zotarolimus-eluting stent in real-world Japanese patients with coronary artery disease (OPERA): Study design and rationale" @default.
• W1857930572 cites W1527614413 @default.
• W1857930572 cites W1590387607 @default.
• W1857930572 cites W17415692 @default.
• W1857930572 cites W1969313733 @default.
• W1857930572 cites W1975033853 @default.
• W1857930572 cites W1976394282 @default.
• W1857930572 cites W1982692220 @default.
• W1857930572 cites W1993611860 @default.
• W1857930572 cites W1998792752 @default.
• W1857930572 cites W2029751100 @default.
• W1857930572 cites W2034630057 @default.
• W1857930572 cites W2036193982 @default.
• W1857930572 cites W2049120615 @default.
• W1857930572 cites W2052806549 @default.
• W1857930572 cites W2053379248 @default.
• W1857930572 cites W2055149005 @default.
• W1857930572 cites W2064290326 @default.
• W1857930572 cites W2087150869 @default.
• W1857930572 cites W2092998815 @default.
• W1857930572 cites W2102296549 @default.
• W1857930572 cites W2103798714 @default.
• W1857930572 cites W2106820552 @default.
• W1857930572 cites W2116772666 @default.
• W1857930572 cites W2148403715 @default.
• W1857930572 cites W2150086052 @default.
• W1857930572 cites W2321857568 @default.
• W1857930572 cites W2744105079 @default.
• W1857930572 cites W4247201646 @default.
• W1857930572 cites W46654976 @default.
• W1857930572 doi "https://doi.org/10.1002/ccd.25282" @default.
• W1857930572 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24382824" @default.
• W1857930572 hasPublicationYear "2013" @default.
• W1857930572 type Work @default.
• W1857930572 sameAs 1857930572 @default.
• W1857930572 citedByCount "3" @default.
• W1857930572 countsByYear W18579305722015 @default.
• W1857930572 countsByYear W18579305722016 @default.
• W1857930572 countsByYear W18579305722019 @default.
• W1857930572 crossrefType "journal-article" @default.
• W1857930572 hasAuthorship W1857930572A5001421629 @default.
• W1857930572 hasAuthorship W1857930572A5003621363 @default.
• W1857930572 hasAuthorship W1857930572A5005993128 @default.
• W1857930572 hasAuthorship W1857930572A5012624832 @default.
• W1857930572 hasAuthorship W1857930572A5022678421 @default.
• W1857930572 hasAuthorship W1857930572A5023883550 @default.
• W1857930572 hasAuthorship W1857930572A5029785850 @default.
• W1857930572 hasAuthorship W1857930572A5037592709 @default.
• W1857930572 hasAuthorship W1857930572A5052154025 @default.
• W1857930572 hasAuthorship W1857930572A5062108209 @default.
• W1857930572 hasAuthorship W1857930572A5071117344 @default.
• W1857930572 hasAuthorship W1857930572A5077511836 @default.
• W1857930572 hasAuthorship W1857930572A5078418468 @default.
• W1857930572 hasConcept C126322002 @default.
• W1857930572 hasConcept C141071460 @default.
• W1857930572 hasConcept C164705383 @default.
• W1857930572 hasConcept C203092338 @default.
• W1857930572 hasConcept C2777546689 @default.
• W1857930572 hasConcept C2778213512 @default.
• W1857930572 hasConcept C2778583881 @default.
• W1857930572 hasConcept C2779464278 @default.
• W1857930572 hasConcept C2780400711 @default.
• W1857930572 hasConcept C2780797203 @default.
• W1857930572 hasConcept C500558357 @default.
• W1857930572 hasConcept C535046627 @default.
• W1857930572 hasConcept C71924100 @default.
• W1857930572 hasConceptScore W1857930572C126322002 @default.
• W1857930572 hasConceptScore W1857930572C141071460 @default.
• W1857930572 hasConceptScore W1857930572C164705383 @default.
• W1857930572 hasConceptScore W1857930572C203092338 @default.
• W1857930572 hasConceptScore W1857930572C2777546689 @default.
• W1857930572 hasConceptScore W1857930572C2778213512 @default.
• W1857930572 hasConceptScore W1857930572C2778583881 @default.
• W1857930572 hasConceptScore W1857930572C2779464278 @default.
• W1857930572 hasConceptScore W1857930572C2780400711 @default.
• W1857930572 hasConceptScore W1857930572C2780797203 @default.
• W1857930572 hasConceptScore W1857930572C500558357 @default.
• W1857930572 hasConceptScore W1857930572C535046627 @default.
• W1857930572 hasConceptScore W1857930572C71924100 @default.
• W1857930572 hasIssue "3" @default.
• W1857930572 hasLocation W18579305721 @default.

• next